Parkinson treatment would be in pharmacies for many years … But no one noticed

Sometimes the drug that was developed against the disease may be the first really useful tool against another. It has passed many times throughout the history of pharmacology and, perhaps, much more will happen. In fact, one of them can lead to receipt Parkinson treatment It has been in pharmacies for a long time.

This is about NIVOLUMAB/RELATLIMABa medicine that is usually used for Melanoma treatmentThe field as was discovered last year by a team of scientists from University of John HopkinsThis drug inhibits protein, which also plays an important role in the development of Parkinson. Therefore, this can be used as a treatment.

Of course, before considering this medicine as treatment with parkinson, this is important Perform a lot of testsThe first field, made a year ago, consisted of analyzing genetically modified mouse brains, so as not to wear some proteins associated with both the disease and the drug.

For the second, of which the results have not yet been published, it was supposed to use direct models with diseases directly As own or disease Alzheimer ParkinsonThe field then, if everything goes well, perhaps clinical trials will arrive at people. It is positive that this is a medicine that has already passed through clinical trials for the treatment of another disease, so some steps will be shorter.

Squirrels that are poisonous neurons

Parkinson is a little -known disease for how much it was studied. There are many more unknown people about how this happens, although it is clear that all patients have many Sinuclein alpha heavier In their nerve cells.

This is a protein that usually helps neurons to communicate with each other, but, poorly built, it can be very harmful to them. Initially, this cannot be uncomfortable, since this is poorly built sinuclein He has no way to penetrate the cells And transport from each other. The problem is that there are two proteins that give him a hand: LAG3 and APLP1At first, it was believed that only the first made, but it was also noted that if he was depressed, Alpha Sinuclein continued to spread through neurons. This meant that he should have a protein that helped him. This is how the study began, which led to the detection of the role of APLP1 in this disease.

The authors of the study published last year believed that this knowledge could advance the development of treatment against Parkinson. To see if they were right, they resorted to genetically modified mice so as not to encode LAG3, APLP1 or not. They saw that both reduced the transport of alpha -synuclein separately, but the effect was especially good when they joined both. In this case, it penetrated 90 % less than this poorly complicated protein in nerve cells.

What will be the treatment against Parkinson?

The drug against the melanoma mentioned above inhibits only LAG3. Therefore, it should be expected to slightly reduce the transportation of harmful proteins. However, trying this in the mice, it was noticed that also They act in the interaction of LAG3 with APLP1. This means that inhibition of one also affects the other. It can be good treatment against Parkinson.

Now it remains only to know when Clinical trials in people. It should be noted that there were always doubts about whether the poorly stuck blue products or the symptom of Parkinson are poorly stuck. To know this, it is not enough to use mice that do not contain a concrete gene. Analysis is necessary, such as the one that will be carried out in laboratory models of animals. We hope that soon we will have such optimistic results as the first about this handling with Parkinson.